Last reviewed · How we verify
Nuvaring
At a glance
| Generic name | Nuvaring |
|---|---|
| Also known as | Contraceptive vaginal ring, contraceptive vaginal ring |
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke. [See Contraindications (4) .] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Common side effects
- Vaginitis
- Headache (including migraine)
- Mood changes (depression, mood swings, mood altered, depressed mood, affect lability)
- Device-related events (expulsion/discomfort/foreign body sensation)
- Nausea/vomiting
- Vaginal discharge
- Increased weight
- Vaginal discomfort
- Breast pain/discomfort/tenderness
- Dysmenorrhea
- Abdominal pain
- Acne
Serious adverse events
- Deep vein thrombosis
- Stroke/cerebrovascular accident
- Arterial thromboembolism
- Myocardial infarction
- Anxiety
- Cholelithiasis
- Vomiting
- Anaphylaxis
- Angioedema
- Device breakage
Key clinical trials
- Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS (PHASE4)
- Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity (PHASE4)
- Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring (PHASE1)
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) (PHASE3)
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012) (PHASE2)
- Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733) (PHASE4)
- Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063) (PHASE3)
- An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nuvaring CI brief — competitive landscape report
- Nuvaring updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI